Connecticut Opened a New Cannabis Lane While Its Market Came Under Constitutional Fire
Connecticut Opened a New Cannabis Lane While Its Existing Market Came Under Constitutional Fire - Pequot Compact / Smith vs Lamont
Front Page › Archive › June 2026
Connecticut Opened a New Cannabis Lane While Its Existing Market Came Under Constitutional Fire - Pequot Compact / Smith vs Lamont
At Connecticut CannaTimes, we don’t decide what’s important behind closed doors; we want you to help shape our investigations.
For years, the state treated cannabis licenses like golden tickets. Limited licenses. Lottery windows. Application fees. Social Equity Council reviews. DCP bottlenecks. Ownership audits. Residency tests. Income tests. Backer scrutiny. Management agreement restrictions. Years of delay.
Connecticut’s adult-use cannabis program was sold as “responsible and equitable.” But two records now point to a deeper structural problem.
A phrase buried within a June 2, 2026 Social Equity Council legislative update may raise uncomfortable questions for patients, advocates, and cannabis entrepreneurs across Connecticut.
A routine Connecticut Social Equity Council meeting took an unexpected turn on May 5 when a discussion about liability protections, legal disclaimers, and loan programs evolved into a public disagreement over the relationship between Council members and agency staff.
The phrase “fentanyl-laced cannabis” is frightening because fentanyl is frightening. Nobody serious should minimize fentanyl. It is potent, dangerous, and responsible for mass overdose deaths across the country.
Bridgeport Police announced this week that cannabis and THC products seized from Dice Convenience Smoke Shop at 4016 Main Street “tested positive for the presence of fentanyl.”
As Connecticut prepares to distribute millions of dollars in cannabis tax revenue through the Social Equity Council’s Reimagine & Revitalize (R2) Community Reinvestment Program, an uncomfortable question is emerging:
When Connecticut legalized cannabis, lawmakers made a promise.
CT CannaTimes is seeking information from patients and consumers who may have purchased or consumed the cannabis flower product identified as 5EPU33-SC (Permanent Urkel). A review of laboratory records provided to CT CannaTimes shows what appears to be a significant discrepancy between two Certificates of Analysis (COAs) associated with the same product identifier.
CT CannaTimes is seeking information from Connecticut cannabis patients and consumers regarding a Brix Cannabis flower product identified during a review of Connecticut cannabis testing records.
For consumers with mold sensitivities, asthma, severe allergies, immunocompromising conditions, or other respiratory concerns.